Predict your next investment

Advisory
novalislifesciences.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

1

Funds

2

About Novalis LifeSciences

Novalis LifeSciences is an investment and advisory firm for the Life Science industry.

Novalis LifeSciences Headquarter Location

1 Liberty Lane E Suite 112

Hampton, New Hampshire, 03842,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Novalis LifeSciences News

Venture Capital: Enko, Which Uses AI To Discover Crop Protection Molecules, Raises $70M

Jul 31, 2022

Molecules, Raises $70M 1d agoVenture CapitaldailyaltsViews: 4 Enko announced its $70 million Series C funding round led by agrochem company Nufarm with participation by Anterra Capital, Taher Gozal, the Bill & Melinda Gates Foundation, Eight Roads Ventures, Finistere Ventures, Novalis LifeSciences, Germin8 Ventures, TO Ventures Food, Endeavor8, Alumni Ventures Group and Rabo Food & Agri Innovation Fund. Not a member yet? Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN

Novalis LifeSciences Investments

15 Investments

Novalis LifeSciences has made 15 investments. Their latest investment was in Animol Discovery as part of their Series B on July 7, 2022.

CBI Logo

Novalis LifeSciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/28/2022

Series B

Animol Discovery

$34M

Yes

2

7/27/2022

Series C

Enko Chem

$70M

No

4

5/5/2022

Series C

Vizgen

$85.2M

No

3

3/8/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/18/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/28/2022

7/27/2022

5/5/2022

3/8/2022

1/18/2022

Round

Series B

Series C

Series C

Series B

Series B

Company

Animol Discovery

Enko Chem

Vizgen

Subscribe to see more

Subscribe to see more

Amount

$34M

$70M

$85.2M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

3

10

10

Novalis LifeSciences Portfolio Exits

1 Portfolio Exit

Novalis LifeSciences has 1 portfolio exit. Their latest portfolio exit was Biotalys on July 01, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/1/2021

IPO

$99M

Public

2

Date

7/1/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

2

Novalis LifeSciences Fund History

2 Fund Histories

Novalis LifeSciences has 2 funds, including Novalis LifeSciences Investments II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/8/2021

Novalis LifeSciences Investments II

$300M

1

7/18/2019

Novalis LifeSciences Investments I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/8/2021

7/18/2019

Fund

Novalis LifeSciences Investments II

Novalis LifeSciences Investments I

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$300M

$99M

Sources

1

10

Novalis LifeSciences Team

1 Team Member

Novalis LifeSciences has 1 team member, including current Managing Director, Devin Leake.

Name

Work History

Title

Status

Devin Leake

Managing Director

Current

Name

Devin Leake

Work History

Title

Managing Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.